Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024
Open Access
- 19 January 2025
- journal article
- research article
- Published by Elsevier in Preventive Medicine Reports
- Vol. 50, 102981
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 30 references indexed in Scilit:
- A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18–49 year old patientsVaccine, 2020
- Safety of live attenuated herpes zoster vaccine in adults 70–79 years: A self-controlled case series analysis using primary care data from Australia’s MedicineInsight programVaccine, 2020
- Review of the initial post-marketing safety surveillance for the recombinant zoster vaccineVaccine, 2020
- Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trialsVaccine, 2019
- Herpes zoster vaccine live: A 10 year review of post-marketing safety experienceVaccine, 2017
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or OlderNew England Journal of Medicine, 2016
- Epidemiology of Herpes Zoster OphthalmicusOphthalmology, 2016
- Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2015
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2011